Recent Announcements
Innovative Research, Inclusive Trials, and New Funding Drives Hope for People with Parkinson’s Disease
PhotoPharmics, an innovator in Parkinson’s disease research and treatment, today announced the successful first close of an $18 million investment round. The investment round, led by Kickstart Fund, a venture capital firm based in Salt Lake City, marks a significant milestone in PhotoPharmics’ mission to revolutionize Parkinson’s disease treatment.
The primary purpose of this investment round is to fund a pivotal clinical trial aimed at obtaining FDA market authorization for Celeste PhotoPharmics’ FDA breakthrough therapeutic device for Parkinson’s disease. In research to this point, the innovative therapy has shown remarkable potential in improving overall function and quality of life for people with Parkinson’s disease.
Kent Savage, CEO of PhotoPharmics, expressed his gratitude for the support of investors, stating, “This investment is a pivotal moment in our journey to transform the treatment landscape for Parkinson’s disease. With this funding, we are positioned to advance our research and bring hope to the millions of individuals living with Parkinson’s.”
Featured Article
How Parkinson’s Affects Sleep and Vice-Versa
When most people think of Parkinson’s Disease (PD), the first symptom to come to mind are physical tremors and other movement symptoms. However, most people with Parkinson’s experience a wide range of non-motor symptoms that can often be more disruptive to their daily...
How Parkinson’s Affects Sleep and Vice-Versa
When most people think of Parkinson’s Disease (PD), the first symptom to come to mind are physical tremors and other movement symptoms. However, most people with Parkinson’s experience a wide range of non-motor symptoms that can often be more disruptive to their daily...
Problem displaying Facebook posts. Backup cache in use.
Click to show error
Archived Content